Longer, thicker looking lashes 100% all yours! GrandeLASH-MD is created with a proprietary blend of vitamins, peptides, and amino acids plus conditioning ingredients. Our award winning eyelash enhancing serum promotes a more youthful, healthy and dramatic lash look. GrandeLASH-MD is safe, effective, and results can be seen in as little as 4 weeks (with full results in 3 months).
1.CAN I EXPECT SOME NEGATIVE SKIN REACTIONS?
Our clinical report has shown that 3% of the patients in the clinical study experienced some tingling or slight stinging, which disappeared after 3 to 5 days.
2. CAN I USE GRANDELASH-MD WHEN I'M PREGNANT OR BREASTFEEDING?
No, GrandeLASH-MD has not been tested on pregnant or breastfeeding women so you cannot use GrandeLASH-MD whilst pregnant, breastfeeding or undergoing chemotherapy.
3. CAN I USE GRANDELASH-MD WHEN I'M UNDERGOING CHEMOTHERAPY?
No. Wait until the treatment is over.
4. I'M USING A SIMILAR PRODUCT BUT HAVE RUN OUT. CAN I USE GRANDELASH-MD INSTEAD?
Normally when we have a new customer convert to GrandeLASH-MD from a different lash serum, we recommend you take a break for AT LEAST a month before starting GrandeLASH-MD. The reasoning behind this is because we are unsure of the content and the effects of the ingredients in other lash serums with GrandeLASH-MD. We have heard of some customers whose lashes have shed due to over stimulating the last folicle. After taking a month break from using a different lash serum, you can start using GrandeLASH-MD.
How to Apply
After cleansing your face, apply GrandeLASH-MD like a liquid eyeliner on your upper lashes before bed. Apply product to eyebrows in thinning areas as well. Consistency is the key, so make sure you keep the serum somewhere in plain eyesight each day and you remember to use it every night to achieve the results even faster.
Results of Clinical Trials.
• 55 patients aged 25 to 62 years.
• Definitive improvement in density, length, thickness in 89%.
• 30 – 40 days noticeability.
• 11% no noticeable change.
• Initial eyelid irritation in 2 patients – but resolved.